Repligen (RGEN) Competitors

Biogen (NASDAQ:BIIB) and Repligen (NASDAQ:RGEN) are both medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their media sentiment, earnings, dividends, community ranking, profitability, institutional ownership, risk, analyst recommendations and valuation.

Is BIIB or RGEN more profitable?

Biogen has a net margin of 16.87% compared to Repligen's net margin of -4.64%. Biogen's return on equity of 14.98% beat Repligen's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Biogen	16.87%	14.98%	8.76%
Repligen	-4.64%	4.21%	2.94%

Does the MarketBeat Community believe in BIIB or RGEN?

Biogen received 1402 more outperform votes than Repligen when rated by MarketBeat users. Likewise, 71.31% of users gave Biogen an outperform vote while only 67.15% of users gave Repligen an outperform vote.

Company	Underperform	Outperform
Biogen	Outperform Votes 1819 71.31%	Underperform Votes 732 28.69%
Repligen	Outperform Votes 417 67.15%	Underperform Votes 204 32.85%

Does the media prefer BIIB or RGEN?

In the previous week, Biogen had 13 more articles in the media than Repligen. MarketBeat recorded 46 mentions for Biogen and 33 mentions for Repligen. Repligen's average media sentiment score of 1.07 beat Biogen's score of 0.62 indicating that Repligen is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Biogen	22 Very Positive mention(s)	1 Positive mention(s)	10 Neutral mention(s)	2 Negative mention(s)	0 Very Negative mention(s)	Positive
Repligen	15 Very Positive mention(s)	1 Positive mention(s)	10 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive

Do institutionals and insiders believe in BIIB or RGEN?

87.9% of Biogen shares are owned by institutional investors. Comparatively, 97.6% of Repligen shares are owned by institutional investors. 0.2% of Biogen shares are owned by insiders. Comparatively, 1.2% of Repligen shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

Which has stronger valuation and earnings, BIIB or RGEN?

Biogen has higher revenue and earnings than Repligen. Repligen is trading at a lower price-to-earnings ratio than Biogen, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Biogen	$9.68B	1.83	$1.63B	$11.19	10.82
Repligen	$634.44M	12.21	$35.60M	-$0.51	-270.57

Which has more risk and volatility, BIIB or RGEN?

Biogen has a beta of 0.06, meaning that its share price is 94% less volatile than the S&P 500. Comparatively, Repligen has a beta of 1.27, meaning that its share price is 27% more volatile than the S&P 500.

Do analysts recommend BIIB or RGEN?

Biogen presently has a consensus target price of $201.93, suggesting a potential upside of 66.77%. Repligen has a consensus target price of $173.25, suggesting a potential upside of 25.55%. Given Biogen's higher probable upside, research analysts plainly believe Biogen is more favorable than Repligen.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Biogen	0 Sell rating(s)	20 Hold rating(s)	12 Buy rating(s)	0 Strong Buy rating(s)	2.38
Repligen	0 Sell rating(s)	5 Hold rating(s)	9 Buy rating(s)	0 Strong Buy rating(s)	2.64

Summary

Biogen beats Repligen on 12 of the 18 factors compared between the two stocks.